Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)

Tipranks - Tipranks - Tue Apr 14, 4:58AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP).

Claim 30% Off TipRanks

Johnson & Johnson (JNJ)

Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson today and set a price target of $234.00. The company’s shares closed last Friday at $238.46.

According to TipRanks.com, Miksic is a 4-star analyst with an average return of 2.7% and a 51.5% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $254.93, implying a 5.3% upside from current levels. In a report issued on April 2, J.P. Morgan also maintained a Hold rating on the stock with a $250.00 price target.

See today’s best-performing stocks on TipRanks >>

BeOne Medicines (ONC)

TD Cowen analyst Yaron Werber reiterated a Buy rating on BeOne Medicines today and set a price target of $424.00. The company’s shares closed last Friday at $309.66.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 23.3% and a 58.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Terns Pharmaceuticals, and Ionis Pharmaceuticals. ;'>

BeOne Medicines has an analyst consensus of Strong Buy, with a price target consensus of $400.71, implying a 27.3% upside from current levels. In a report issued on April 6, Truist Financial also reiterated a Buy rating on the stock with a $412.00 price target.

Helus Pharma (HELP)

Helus Pharma received a Buy rating and an $8.00 price target from TD Cowen analyst Ritu Baral today. The company’s shares closed last Friday at $5.22.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 43.2% and a 53.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Sionna Therapeutics, Inc. ;'>

Currently, the analyst consensus on Helus Pharma is a Strong Buy with an average price target of $41.17.

Read More on JNJ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).